Philips and UC Irvine partner to develop standards for breast cancer screening

-- Study will assess the clinical accuracy of spectral imaging technology with low radiation dose to measure breast density, potentially increasing accuracy of cancer detection and arming patients with better tools for care

ANDOVER, Massachusetts, March 5, 2015 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA) today announced its collaboration with the University of California, Irvine, to explore how spectral breast imaging can improve breast density measurement, potentially aiding clinicians in more accurately gauging breast cancer risks and monitoring changes over time. The study will rely on Philips' MicroDose SI mammography spectral imaging technology. Designed to address the industry's growing concern about the lower diagnostic accuracy of mammography for high density breasts, MicroDose SI joins Philips' suite of diagnostic imaging solutions designed to enhance imaging quality for confident diagnostics at a low dose.

Logo - http://photos.prnewswire.com/prnh/20140122/NE50581LOGO

Studies have shown that high breast density increases the risk of developing breast cancer. In fact, women with dense tissue in 75 percent or more of the breast have a risk of breast cancer four to six times as great as the risk among women with little or no dense tissue.  Higher breast density may also make breast cancer more difficult to detect by mammography. The ability to more accurately measure breast density will enable radiologists to personalize breast cancer screenings and potentially be used for treatment monitoring.

With MicroDose SI, Philips introduced its first spectral imaging application with a new feature called Spectral Breast Density Measurement. Rather than estimating density, the tool uses photon counting technology to simultaneously acquire spectral data of the adipose and fibroglandular tissue within a single exposure of a low dose mammogram. This provides an objective volumetric breast density measurement, paving the way for refined risk assessment and personalized care.

"Through this study, UC Irvine and Philips are looking to set an industry standard for objectively measuring breast density. While this doesn't exist today, it will be increasingly critical as we move toward further personalizing breast cancer screening, and enabling patients to become more engaged in their own care," said Gene Saragnese, CEO Imaging, Philips. "With the combination of our MicroDose SI technology and leading imaging experts at UC Irvine, we can determine if spectral breast imaging can help provide more definitive diagnoses, at low radiation dose, to better help patients and clinicians in the fight against breast cancer."

The first phase of the study will focus on assessing the accuracy of the spectral breast density application by analyzing 40 post-mortem breasts and comparing results with chemical analysis. The study is expected to be completed over a one- to two-year-long period.

"One of the biggest challenges for us has been the lack of quantitative standards, which makes it very difficult to prove the accuracy of breast density measurements," said Sabee Molloi, Ph.D., professor of radiological sciences at the University of California, Irvine School of Medicine and the study's lead researcher. "Leveraging Philips' spectral imaging technology, this study will help us validate breast density measurements and set industry standards, which can help enhance the quality of diagnoses and treatment."

For more information on Philips innovative imaging systems that focus on the health continuum from prevention, screening and diagnosis, to treatment, recovery and home care, visit www.philips.com/healthcare and follow @PhilipsHealth.

For further information, please contact:
Kathy O'Reilly
Philips
Tel: +1 978-659-2638
Mobile: +1 978-221-8919
Email: kathy.oreilly@philips.com 
Twitter: @kathyoreilly

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 105,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.

Related Links

http://www.philips.com/healthcare

SOURCE Royal Philips